Search Result

Results for "

Navicixizumab (OMP-305B83) 是一种双特异性抗 <b>VEGF</b> 和抗 <b>DLL4</b> 抑制抗体。Navicixizumab 可以与紫杉醇结合用于癌症研究。Navicixizumab 可用于卵巢癌、原发性腹膜癌或输卵管癌的研究。

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (4) Apoptosis (8) Aryl Hydrocarbon Receptor (1) Autophagy (3) Bacterial (3) Beclin1 (2) Complement System (3) COX (3) Drug Metabolite (1) EBI2/GPR183 (1) Endogenous Metabolite (3) Estrogen Receptor/ERR (1) FXR (1) HCV (1) HIF/HIF Prolyl-Hydroxylase (12) Histamine Receptor (6) Integrin (4) Interleukin Related (1) Isotope-Labeled Compounds (2) JNK (2) Macrophage migration inhibitory factor (MIF) (1) MAP3K (1) Microtubule/Tubulin (1) MMP (3) Monoamine Oxidase (1) NF-κB (2) Notch (5) Parasite (1) PD-1/PD-L1 (1) PDGFR (1) PKC (1) PKD (1) Reactive Oxygen Species (1) SARS-CoV (1) Small Interfering RNA (siRNA) (4) TAM Receptor (1) Tie (1) Tyrosinase (1) VEGFR (47) Wnt (2)
By Research Areas:	Cancer (56) Cardiovascular Disease (19) Endocrinology (4) Infection (4) Inflammation/Immunology (14) Metabolic Disease (8) Neurological Disease (1)

By Targets:

Akt (3)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (4)

Apoptosis (8)

Aryl Hydrocarbon Receptor (1)

Autophagy (3)

Bacterial (3)

Beclin1 (2)

Complement System (3)

COX (3)

Drug Metabolite (1)

EBI2/GPR183 (1)

Endogenous Metabolite (3)

Estrogen Receptor/ERR (1)

FXR (1)

HCV (1)

HIF/HIF Prolyl-Hydroxylase (12)

Histamine Receptor (6)

Integrin (4)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

JNK (2)

Macrophage migration inhibitory factor (MIF) (1)

MAP3K (1)

Microtubule/Tubulin (1)

MMP (3)

Monoamine Oxidase (1)

NF-κB (2)

Notch (5)

Parasite (1)

PD-1/PD-L1 (1)

PDGFR (1)

PKC (1)

PKD (1)

Reactive Oxygen Species (1)

SARS-CoV (1)

Small Interfering RNA (siRNA) (4)

TAM Receptor (1)

Tie (1)

Tyrosinase (1)

VEGFR (47)

Wnt (2)

By Research Areas:

Cancer (56)

Cardiovascular Disease (19)

Endocrinology (4)

Infection (4)

Inflammation/Immunology (14)

Metabolic Disease (8)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99261

Demcizumab OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody	Notch	Cancer
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .

HY-P99377

*Navicixizumab* OMP-305B83; Anti-DLL4 Reference Antibody (Navicixizumab)	Notch	Cancer
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

HY-RS03810

DLL4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DLL4 Human Pre-designed siRNA Set A contains three designed siRNAs for DLL4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DLL4 Human Pre-designed siRNA Set A DLL4 Human Pre-designed siRNA Set A

HY-P99852

Dilpacimab ABT165; PR1283233	VEGFR	Cancer
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and *VEGF* pathways.. Dilpacimab can be used in research of cancer .

HY-122094

Steppogenin	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Cancer
Steppogenin is a potent inhibitor of HIF-1α and *DLL4, with IC₅₀* values of 0.56 and 8.46 μM, respectively. Steppogenin can be sued for the research of angiogenic diseases, such as those involving solid tumors .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human *Dll4. DLL4* is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-RS09784

OMP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
OMP Human Pre-designed siRNA Set A contains three designed siRNAs for OMP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OMP Human Pre-designed siRNA Set A OMP Human Pre-designed siRNA Set A

HY-P9951A

*Ranibizumab (anti-VEGF)* RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, Humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity .

HY-P99320

Tarextumab OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody	Notch	Cancer
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .

HY-P99667

Ipafricept OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is the first class of recombinant fusion proteins, consisting of the extracellular portion of the human fried-8 receptor fused to the Fc fragment of human IgG1 binding to the Wnt ligand. Ipafricept shows solid tumor inhibition activity, with well tolerance .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

*Aflibercept (VEGF* Trap)**	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P5558

KLTWQELYQLKYKGI	VEGFR	Inflammation/Immunology
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. KLTWQELYQLKYKGI shows the ability to induce capillary formation and organization in vitro .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-18185

JNJ 17029259	VEGFR	Cancer
JNJ 17029259 is an orally active and selective *VEGF-R2* kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity .

HY-P9906

Bevacizumab Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity.

HY-109561

Pegaptanib sodium EYE001; NX1838	VEGFR	Metabolic Disease Inflammation/Immunology
Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-108868

Mersalyl Salirgan; Salurin; Salyrgan	HIF/HIF Prolyl-Hydroxylase VEGFR	Metabolic Disease
Mersalyl (Salirgan) is a potent vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) inducer. Mersalyl induces VEGF and ENO1 mRNA expression. Mersalyl shows diuresis effects .

HY-N7177

Hydroxytanshinone IIA	Drug Metabolite VEGFR	Cancer
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-P5107

Protein LMWP	VEGFR	Cancer
Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Protein LMWP can inhibit tumor growth and is used in cancer research .

HY-146412

Vanin-1-IN-3

Others Metabolic Disease

Vanin-1-IN-3 (OMP-7) is a vanin-1 inhibitor with an IC₅₀ of 0.038 μM .

Vanin-1-IN-3	Others	Metabolic Disease
Vanin-1-IN-3 (OMP-7) is a vanin-1 inhibitor with an IC₅₀ of 0.038 μM .

HY-13892

Dovitinib dilactic acid CHIR-258 dilactic acid; TKI258 dilactic acid	VEGFR	Cancer
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .

HY-151465

HIF-1α-IN-4	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-4 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-4 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-4 can be used in the research of cancer .

HY-P5133

Synstatin (92-119) SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 .

HY-115436

LYG-202	Apoptosis	Cancer
LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .

HY-135671

AhR modulator-1	Aryl Hydrocarbon Receptor VEGFR Estrogen Receptor/ERR	Endocrinology Cancer
AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus .

HY-17369

Tirofiban hydrochloride monohydrate 1 Publications Verification L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369B

Tirofiban 1 Publications Verification L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-P99416

Abicipar pegol AGN-150998; MP0112	VEGFR	Cardiovascular Disease Inflammation/Immunology
Abicipar pegol (AGN-150998, MP0112) is an anti-VEGF DARPin molecule, a novel class of small proteins containing ankyrin repeat domains engineered to bind with high specificity and affinity to target proteins. Abicipar pegol effectively inhibits angiogenesis and vascular permeability and is used in the study of diseases related to ocular inflammation by intravitreal injection, reducing mean retinal thickness and leakage area .

HY-151466

HIF-1α-IN-5	HIF/HIF Prolyl-Hydroxylase Monoamine Oxidase	Cancer
HIF-1α-IN-5 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-5 also inhibits MAO-A activity. HIF-1α-IN-5 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-5 can be used in the research of cancer .

HY-162011

GPR183 antagonist-2	EBI2/GPR183	Inflammation/Immunology
GPR183 antagonist-2 (compound 32) is a selective GPR183 antagonist with good water solubility and excellent pharmacokinetic properties. GPR183 antagonist-2 significantly reduces paw and joint swelling and gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a collagen-induced arthritis (CIA) mouse model in a dose-dependent manner. GPR183 antagonist-2 can be used in the study of autoimmune diseases .

HY-P9951

Ranibizumab RG-6321	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-B0223

Albendazole 3 Publications Verification SKF-62979	Parasite Microtubule/Tubulin Autophagy Apoptosis Reactive Oxygen Species VEGFR HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial	Infection Cancer
Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, *VEGF* expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells ^[4] .

HY-147712

PKC-IN-4	PKC	Inflammation/Immunology
PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC₅₀ of 0.52 µM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both **VEGF isoforms and C3b/C4b**. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-N2666

5α-Hydroxycostic acid	VEGFR	Cancer
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and Ang2/Tie2 pathways .

HY-P99675

Ivonescimab

AK112
PD-1/PD-L1 VEGFR Cancer

Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research .

Ivonescimab AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a *PD-1/VEGF* Bispecific Antibody. Ivonescimab can be used for cancer research .

HY-P9920

Ramucirumab 2 Publications Verification	VEGFR	Cancer
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-147762

NRP1 antagonist 2

Complement System Cancer

NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist .

NRP1 antagonist 2	Complement System	Cancer
NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist .

HY-153484A

Bevasiranib sodium	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-153484

Bevasiranib	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-137941

Roxatidine	Histamine Receptor	Inflammation/Immunology
Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is a histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect .

HY-B0164

Mizolastine	Histamine Receptor	Inflammation/Immunology
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of *VEGF165, VEGF120, TNF-α* and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-B0164A

Mizolastine dihydrochloride	Histamine Receptor	Inflammation/Immunology
Mizolastine dihydrochloride is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine dihydrochloride effectively inhibits mRNA expression of *VEGF165, VEGF120, TNF-α* and KC. Mizolastine dihydrochloride can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-112547

CRT5 CRT0066051	PKD	Others
CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of PKD in endothelial cells treated with VEGF (IC₅₀s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis .

Cat. No.	Product Name

HY-L125

Anti-Pulmonary Fibrosis Compound Library

1692 compounds

Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 1692 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

HY-L088

2003 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 2003 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

HY-L103

Anti-Colorectal Cancer Compound Library

1630 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1630 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P5558

KLTWQELYQLKYKGI	VEGFR	Inflammation/Immunology
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. KLTWQELYQLKYKGI shows the ability to induce capillary formation and organization in vitro .

HY-P5133

Synstatin (92-119) SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 .

HY-P1663

ATWLPPR Peptide 1 Publications Verification	Peptides	Others
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)

HY-P5107

Protein LMWP	VEGFR	Cancer
Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Protein LMWP can inhibit tumor growth and is used in cancer research .

HY-P4253

Arginyl-Glutamine	VEGFR	Cardiovascular Disease
Arginyl-Glutamine is a dipeptide that can decrease *VEGF* levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .

HY-P5438

Srctide	Peptides	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

HY-P3999

Fibulostatin 6.2

Peptides Cardiovascular Disease

Fibulostatin 6.2 is an anti-angiogenic peptide that can inhibit migration of human umbilical vein endothelial cells in vitro .

HY-P3995

Scospondistatin	Peptides	Cardiovascular Disease
Scospondistatin is an anti-angiogenic peptide that can inhibit proliferation and migration of human umbilical vein endothelial cells in vitro .

HY-13718

Oglufanide H-Glu-Trp-OH; L-Glutamyl-L-tryptophan	VEGFR HCV Endogenous Metabolite	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .

Cat. No.	Product Name	Target	Research Area

HY-P99261

Demcizumab OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody	Notch	Cancer
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .

HY-P99377

*Navicixizumab* OMP-305B83; Anti-DLL4 Reference Antibody (Navicixizumab)	Notch	Cancer
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

HY-P990252

*Anti-Mouse Delta-like protein 4/DLL4* Antibody (HMD4-2)**	Inhibitory Antibodies	Others
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse Delta-like protein 4/DLL4.

HY-P99852

Dilpacimab ABT165; PR1283233	VEGFR	Cancer
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and *VEGF* pathways.. Dilpacimab can be used in research of cancer .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human *Dll4. DLL4* is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-P99401

Rosmantuzumab OMP-131R10	Inhibitory Antibodies	Cancer
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .

HY-P99876

Efaprinermin alfa OMP-336B11	Inhibitory Antibodies	Others
Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody targeting TNFRSF18. Efaprimermin alfa is a GITR ligand-Fc fusion protein .

HY-P99949

Etigilimab OMP-313M32	Inhibitory Antibodies	Cancer
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing .

HY-P9951A

*Ranibizumab (anti-VEGF)* RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, Humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity .

HY-P99320

Tarextumab OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody	Notch	Cancer
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .

HY-P99667

Ipafricept OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is the first class of recombinant fusion proteins, consisting of the extracellular portion of the human fried-8 receptor fused to the Fc fragment of human IgG1 binding to the Wnt ligand. Ipafricept shows solid tumor inhibition activity, with well tolerance .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

*Aflibercept (VEGF* Trap)**	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .

HY-P9906

Bevacizumab Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity.

HY-P990148

*Anti-Mouse VEGF-A Antibody (2G11-2A05)*	Inhibitory Antibodies	Others
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGF-A.

HY-P99416

Abicipar pegol AGN-150998; MP0112	VEGFR	Cardiovascular Disease Inflammation/Immunology
Abicipar pegol (AGN-150998, MP0112) is an anti-VEGF DARPin molecule, a novel class of small proteins containing ankyrin repeat domains engineered to bind with high specificity and affinity to target proteins. Abicipar pegol effectively inhibits angiogenesis and vascular permeability and is used in the study of diseases related to ocular inflammation by intravitreal injection, reducing mean retinal thickness and leakage area .

HY-P9951

Ranibizumab RG-6321	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both **VEGF isoforms and C3b/C4b**. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P99675

Ivonescimab

AK112
PD-1/PD-L1 VEGFR Cancer

Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research .

HY-P9920

Ramucirumab 2 Publications Verification	VEGFR	Cancer
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-P990082

Suvemcitug

VEGFR Cancer

Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) .

HY-P99116

Faricimab RG7716	VEGFR	Metabolic Disease
Faricimab is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab can be used for diabetic macular edema (DME) research .

HY-P9973

Brolucizumab DLX1008; ESBA 1008; RTH258	VEGFR	Cancer
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (K_D=1.05 pM). Brolucizumab can be used for the research of cancer .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks *VEGF-A* and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .

HY-145633

Sozinibercept OPT 302; VGX-300	VEGFR	Cardiovascular Disease
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of *VEGF-C/D*, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2666

5α-Hydroxycostic acid	Other Terpenoids Classification of Application Fields Terpenoids Source classification Erythrina burttii Baker f. Plants Compositae Disease Research Fields Cancer	VEGFR
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and Ang2/Tie2 pathways .

HY-110066

(Z)-Guggulsterone 2 Publications Verification	Classification of Application Fields Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Disease Research Fields Steroids Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the *VEGF–VEGF-R2–Akt* signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-N0545

Taurocholic acid sodium 5+ Cited Publications Sodium taurocholate; N-Choloyltaurine sodium	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	VEGFR Endogenous Metabolite
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-122094

Steppogenin	Structural Classification Flavonoids Flavones Source classification Maclura tricuspidata Carriere Plants Moraceae	HIF/HIF Prolyl-Hydroxylase
Steppogenin is a potent inhibitor of HIF-1α and *DLL4, with IC₅₀* values of 0.56 and 8.46 μM, respectively. Steppogenin can be sued for the research of angiogenic diseases, such as those involving solid tumors .

HY-N7177

Hydroxytanshinone IIA	Quinones Classification of Application Fields Labiatae Source classification Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Cancer	Drug Metabolite VEGFR
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-B0239

Chloramphenicol 5+ Cited Publications	Structural Classification Classification of Application Fields Anti-aging Source classification Antibacterial Disease Research Endogenous metabolite Other Antibiotics Infection Human Gut Microbiota Metabolites Plant Cell Culture Microorganisms Antibiotics Resistance Selection Animal Husbandry Anticancer Disease Research Fields Cancer	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N0135

Tanshinone IIA Maximum Cited Publications 15 Publications Verification Dan Shen ketone	Quinones Structural Classification Classification of Application Fields Terpenoids Labiatae Source classification Samanea saman (Jacq.) Merr. Diterpenoids Plants Naphthalene Quinones Disease Research Fields Cancer	VEGFR
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-12686

5Z-7-Oxozeaenol 5+ Cited Publications FR148083; L783279; LL-Z 1640-2	Structural Classification Natural Products Monophenols Microorganisms Classification of Application Fields Source classification Phenols Inflammation/Immunology Disease Research Fields	MAP3K VEGFR Antibiotic
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-126114

Lupeol acetate 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Umbelliferae Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray	COX Interleukin Related
Lupeol acetate, a derivative of Lupeol, suppresses the progression of rheumatoid arthritis (RA) by inhibiting the activation of macrophages and osteoclastogenesis through downregulations of TNF-α, IL-1β, MCP-1, COX-2, VEGF and granzyme B .

HY-N0896

Inulicin 1 Publications Verification 1-O-Acetylbritannilactone	Phyllodium pulchellum (L.) Desv. Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Inflammation/Immunology Disease Research Fields	NF-κB COX
Inulicin (1-O-Acetylbritannilactone) is an active compound that inhibits VEGF-mediated activation of Src and FAK. Inulicin (1-O-Acetylbritannilactone) inhibits LPS-induced PGE₂ production and COX-2 expression, and NF-κB activation and translocation.

HY-N0545R

Taurocholic acid sodium (Standard) Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	VEGFR Endogenous Metabolite
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate; N-Choloyltaurine sodium) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Immunoregulation effect .

HY-119767

Jolkinolide A	Structural Classification Euphorbia fischeriana Steud. Terpenoids Source classification Diterpenoids Euphorbiaceae Plants	VEGFR Apoptosis
Jolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of *VEGF* in A549 cells .

HY-13718

Oglufanide H-Glu-Trp-OH; L-Glutamyl-L-tryptophan	Cardiovascular Disease Structural Classification Classification of Application Fields Animals Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	VEGFR HCV Endogenous Metabolite
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .

Species:	Human (47) Rhesus Macaque (1) Mouse (16) Rat (6) E.coli (1) Cynomolgus (2) Rabbit (2) Canine (1) Pig (2)
Tag:	His (42) SUMO (1) Tag Free (18) Avi (13) Myc (1) Fc (15)
Source:	HEK293 (56) CHO (2) Sf9 insect cells (4) P. pastoris (6) E. coli (9)

Cat. No.	Compare	Product Name	Species	Source

HY-P78116

	*Delta-like protein 4/DLL4* Protein, Human (Biotinylated, HEK293, His)** DLL4; MGC126344; notch ligand DLL4; Delta4; Delta-like 4	Human	HEK293
	Delta-like protein 4 (DLL4) functions as a Notch ligand and activates NOTCH1 and NOTCH4 in the Notch signaling pathway. It regulates angiogenesis by inhibiting endothelial cell proliferation, migration, and angiogenesis. Delta-like protein 4/DLL4 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with C-His labeled tag. The total length of Delta-like protein 4/DLL4 Protein, Human (Biotinylated, HEK293, His) is 498 a.a., with molecular weight of 60-70 kDa.

HY-P72972

	*Delta-like protein 4/DLL4* Protein, Human (HEK293)** Delta-like protein 4; Delta4; DLL4	Human	HEK293
	Delta-like protein 4 (DLL4) functions as a Notch ligand and activates NOTCH1 and NOTCH4 in the Notch signaling pathway. It regulates angiogenesis by inhibiting endothelial cell proliferation, migration, and angiogenesis. Delta-like protein 4/DLL4 Protein, Human (HEK293) is the recombinant human-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with tag free. The total length of Delta-like protein 4/DLL4 Protein, Human (HEK293) is 498 a.a., with molecular weight of 55-70 kDa.

HY-P75292

	*Delta-like protein 4/DLL4* Protein, Mouse (HEK293, His)** Delta-like protein 4; Delta4; DLL4	Mouse	HEK293
	Delta-like 4/DLL4 protein is a key player in the Notch signaling pathway, acting as a ligand to activate NOTCH1 and NOTCH4. In angiogenesis, DLL4 regulates endothelial cell proliferation, migration, and angiogenic sprouting. Delta-like protein 4/DLL4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with C-His labeled tag. The total length of Delta-like protein 4/DLL4 Protein, Mouse (HEK293, His) is 525 a.a., with molecular weight of ~68 kDa.

HY-P75294

	*Delta-like protein 4/DLL4* Protein, Human (HEK293, Fc)** Delta-like protein 4; Delta4; DLL4	Human	HEK293
	The DLL4 protein, a homolog of the Drosophila delta gene family, encodes Notch ligands with a DSL domain, EGF repeats, and a transmembrane domain. DLL4 is widely expressed in tissues, including placenta (RPKM 11.5), fat (RPKM 11.2), and 22 others. Delta-like protein 4/DLL4 Protein, Human (HEK293, Fc) is the recombinant human-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Delta-like protein 4/DLL4 Protein, Human (HEK293, Fc) is 498 a.a., with molecular weight of 100-110 kDa.

HY-P75293

	*Delta-like protein 4/DLL4* Protein, Mouse (HEK293, Fc)** Delta-like protein 4; Delta4; DLL4	Mouse	HEK293
	Delta-like 4/DLL4 protein is a key player in the Notch signaling pathway, acting as a ligand to activate NOTCH1 and NOTCH4. In angiogenesis, DLL4 regulates endothelial cell proliferation, migration, and angiogenic sprouting. Delta-like protein 4/DLL4 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of Delta-like protein 4/DLL4 Protein, Mouse (HEK293, Fc) is 525 a.a., with molecular weight of ~80.61 kDa.

HY-P76872

	*Delta-like protein 4/DLL4* Protein, Rhesus Macaque (HEK293, His)** Delta-like protein 4; Delta4; DLL4	Rhesus Macaque	HEK293
	delta-like protein 4 involves in the Notch signaling pathway as Notch ligand, and activates NOTCH1 and NOTCH4. delta-like protein 4 involves in angiogenesis. Delta-like protein 4/DLL4 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with C-His labeled tag. The total length of Delta-like protein 4/DLL4 Protein, Rhesus Macaque (HEK293, His) is 502 a.a., with molecular weight of ~56.1 KDa.

HY-P701309

	*Delta-like protein 4/DLL4* Protein, Human (HEK293, His-Avi)** Delta-like protein 4; Delta4; DLL4	Human	HEK293
	Delta-like protein 4 (DLL4) functions as a Notch ligand and activates NOTCH1 and NOTCH4 in the Notch signaling pathway. It regulates angiogenesis by inhibiting endothelial cell proliferation, migration, and angiogenesis. Delta-like protein 4/DLL4 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with labeled tag. The total length of Delta-like protein 4/DLL4 Protein, Human (HEK293, His-Avi) is 498 a.a., with molecular weight of 62-68 kDa.

HY-P70111

	*Delta-like protein 4/DLL4* Protein, Human (498a.a, HEK293, His)** rHuDelta-like protein 4/DLL4, His; Delta-like protein 4; Drosophila Delta homolog 4; Delta4; DLL4	Human	HEK293
	Delta-like protein 4 (DLL4) functions as a Notch ligand and activates NOTCH1 and NOTCH4 in the Notch signaling pathway. It regulates angiogenesis by inhibiting endothelial cell proliferation, migration, and angiogenesis. Delta-like protein 4/DLL4 Protein, Human (498a.a, HEK293, His) is the recombinant human-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with C-His labeled tag. The total length of Delta-like protein 4/DLL4 Protein, Human (498a.a, HEK293, His) is 498 a.a., with molecular weight of 55-70 kDa.

HY-P73736

	*Olfactory Marker Protein/OMP* Protein, Human (His)** Olfactory marker protein; Olfactory neuronal-specific protein; OMP	Human	E. coli
	OMP Protein acts as a modulator in the olfactory signal-transduction cascade, finely tuning olfactory signaling processes. Interacting with BEX1 and BEX2, OMP suggests potential associations with proteins in cellular processes, emphasizing its multifaceted role in the intricate olfactory signal transduction network and implying broader involvement in the molecular framework of olfactory function. Olfactory Marker Protein/OMP Protein, Human (His) is the recombinant human-derived Olfactory Marker protein/OMP protein, expressed by E. coli , with N-His labeled tag. The total length of Olfactory Marker Protein/OMP Protein, Human (His) is 163 a.a., with molecular weight of ~19 kDa.

HY-P7312

	VEGF164 Protein, Mouse 1 Publications Verification VEGF-AA; rMuVEGF164; VPF	Mouse	E. coli
	VEGF164 Protein, Mouse is a potent mediator of angiogenesis and binds the semaphorin receptor, neuropilin1.

HY-P74476

	VEGF165 Protein, zebrafish (sf9) VEGF-AA; Vascular endothelial growth factor A-A; VEGF; VEGFa	Others	Sf9 insect cells
	The VEGF165 protein is an important growth factor that actively drives vasculogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF165 Protein, zebrafish (sf9) is the recombinant VEGF165 protein, expressed by Sf9 insect cells , with tag free. The total length of VEGF165 Protein, zebrafish (sf9) is 188 a.a., with molecular weight of ~22 kDa.

HY-P7311

	VEGF165 Protein, Rat (CHO) 2 Publications Verification rRtVEGF165; VEGF-AA; VPF	Rat	CHO
	VEGF165 Protein, Rat (CHO) is a potent mediator of angiogenesis and binds the semaphorin receptor, neuropilin1.

HY-P70638

	VEGF164 Protein, Rat (P.pastoris) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VEGF; VPF	Rat	P. pastoris
	The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (P.pastoris) is the recombinant rat-derived VEGF164 protein, expressed by P. pastoris , with tag free. and A36T, , , , mutation. The total length of VEGF164 Protein, Rat (P.pastoris) is 164 a.a., with molecular weight of 18-23 kDa.

HY-P73471

	VEGF121 Protein, Human (HEK293) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF121 Protein, Human (HEK293) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with tag free. The total length of VEGF121 Protein, Human (HEK293) is 147 a.a., with molecular weight of ~19.9 & 17.0 kDa, respectively.

HY-P73556

	VEGF145 Protein, Human (HEK293) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF145 Protein, Human (HEK293) is the recombinant human-derived VEGF145 protein, expressed by HEK293 , with tag free. The total length of VEGF145 Protein, Human (HEK293) is 145 a.a., with molecular weight of ~16.92 kDa.

HY-P77279

	VEGF183 Protein, Human (sf9) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGF	Human	Sf9 insect cells
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF183 Protein, Human (sf9) is the recombinant human-derived VEGF183 protein, expressed by Sf9 insect cells , with tag free. The total length of VEGF183 Protein, Human (sf9) is 183 a.a., with molecular weight of ~21 KDa.

HY-P78377

	VEGF121 Protein, Human (HEK293, His-Avi) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF121 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF121 Protein, Human (HEK293, His-Avi) is 121 a.a., with molecular weight of ~18 kDa & 22-25 kDa, respectively.

HY-P7420

	VEGF121 Protein, Human (120 a.a) 1 Publications Verification VEGF-AA; rHuVEGF-121; VPF	Human	E. coli
	VEGF121 Protein, Human (120 a.a), a VEGF isoform splice variant, cannot bind to heparin. VEGF121 Protein is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers.

HY-P72775

	VEGF120 Protein, Mouse VEGF-AA; Vascular endothelial growth factor A; VPF; VEGFA	Mouse	E. coli
	VEGF-A Protein is a key member of the VEGF family of cytokines. VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability. VEGF-A stimulates endothelial cell mitogenesis and cell migration. VEGF120 Protein, Mouse is the recombinant mouse-derived VEGF120 protein, expressed by E. coli, with tag free. The total length of VEGF120 Protein, Mouse is 120 a.a., with homodimer molecular weight of ~28.4 kDa.

HY-P76122

	VEGF164 Protein, Rat (sf9) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGFA164; VEGF164	Rat	Sf9 insect cells
	The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (sf9) is the recombinant rat-derived VEGF164 protein, expressed by Sf9 insect cells , with tag free. The total length of VEGF164 Protein, Rat (sf9) is 164 a.a., with molecular weight of ~25 kDa.

HY-P70519

	VEGF121 Protein, Human (121a.a, HEK293, His) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGF	Human	HEK293
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF121 Protein, Human (121a.a, HEK293, His) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF121 Protein, Human (121a.a, HEK293, His) is 121 a.a., with molecular weight of 16-18 kDa.

HY-P7421

	VEGF164 Protein, Mouse (186a.a, P.pastoris) 1 Publications Verification VEGF-AA; rMuVEGF164; VPF	Mouse	P. pastoris
	VEGF164 Protein, Mouse (186a.a, P.pastoris), a VEGF isoform splice variant, is more potent at inducing endothelial ICAM-1 expression by VEGFR-2, leukocyte migration by VEGFR-1, and inflammation and angiogenesis in the adult cornea.

HY-P73473

	VEGF-AA Protein, Canine (HEK293) VEGFA; Vascular endothelial growth factor A; VPF; VEGF	Canine	HEK293
	VEGFA Protein is a vascular endothelial growth factor that is active in angiogenesis and endothelial cell growth. VEGFA Protein induces endothelial cell proliferation, promotes cell migration, inhibits cell apoptosis, and induces vascular permeability. VEGFA Protein consists of 214 amino acids (M1-R214). VEGF-AA Protein, Canine (HEK293) is the recombinant canine-derived VEGF-AA protein, expressed by HEK293 , with tag free. The total length of VEGF-AA Protein, Canine (HEK293) is 190 a.a., with molecular weight of ~23 kDa.

HY-P72430

	VEGF-DD Protein, Mouse (HEK293, His) Vascular endothelial growth factor D; VEGF-D; FIGF	Mouse	HEK293
	VEGF-DD Protein, a versatile growth factor, orchestrates angiogenesis, lymphangiogenesis, and endothelial cell growth. It stimulates proliferation, migration, and influences vessel permeability. VEGF-DD binds VEGFR-3, triggering crucial signaling for vascular development. Structurally, VEGF-DD is a non-covalent homodimer, emphasizing its intricate role in vascular processes. VEGF-DD Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGF-DD protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-DD Protein, Mouse (HEK293, His) is 109 a.a., with molecular weight of 17-20 kDa.

HY-P72431

	VEGF-BB Protein, Human (HEK293, Fc) 1 Publications Verification Vascular endothelial growth factor B; VEGF-B; VRF	Human	HEK293
	VEGF-BB protein is an endothelial cell-specific growth factor with VEGF-B167 and VEGF-B186 isoforms and has a unique binding ability to heparin and Neuropilin-1. Structural homodimerization linked by disulfide bonds allows the formation of heterodimers with VEGF, emphasizing its role in regulating endothelial cell function. VEGF-BB Protein, Human (HEK293, Fc) is the recombinant human-derived VEGF-BB protein, expressed by HEK293 , with N-hFc labeled tag. The total length of VEGF-BB Protein, Human (HEK293, Fc) is 186 a.a., with molecular weight of 40 & 60 kDa, respectively.

HY-P73474

	VEGF-DD Protein, Mouse (HEK293, Fc) Vascular endothelial growth factor D; VEGF-D; FIGF	Mouse	HEK293
	VEGF-DD Protein, a versatile growth factor, orchestrates angiogenesis, lymphangiogenesis, and endothelial cell growth. It stimulates proliferation, migration, and influences vessel permeability. VEGF-DD binds VEGFR-3, triggering crucial signaling for vascular development. Structurally, VEGF-DD is a non-covalent homodimer, emphasizing its intricate role in vascular processes. VEGF-DD Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived VEGF-DD protein, expressed by HEK293 , with N-hFc labeled tag. The total length of VEGF-DD Protein, Mouse (HEK293, Fc) is 109 a.a., with molecular weight of ~45 & 36 kDa, respectively.

HY-P73475

	VEGF-DD Protein, Rat (HEK293, Fc) Vascular endothelial growth factor D; VEGF-D; FIGF	Rat	HEK293
	VEGF-DD, a growth factor, stimulates proliferation, migration, and vessel permeability. It is crucial for vascular development and maintenance of lymphatic endothelium. VEGF-DD binds and activates VEGFR-3, initiating essential signaling pathways. Structurally, it forms a non-covalent homodimer, playing an intricate role in vascular processes. VEGF-DD Protein, Rat (HEK293, Fc) is the recombinant rat-derived VEGF-DD protein, expressed by HEK293 , with N-hFc labeled tag. The total length of VEGF-DD Protein, Rat (HEK293, Fc) is 117 a.a., with molecular weight of ~50 kDa.

HY-P70761

	VEGF164 Protein, Mouse (164a.a, P.pastoris) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGFA164; VEGF164	Mouse	P. pastoris
	VEGF-A Protein is a key member of the VEGF family of cytokines. VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability. VEGF-A stimulates endothelial cell mitogenesis and cell migration. VEGF164 Protein, Mouse (164a.a, P.pastoris) is the recombinant mouse-derived VEGF164 protein, expressed by P. pastoris, with tag free. The total length of VEGF164 Protein, Mouse (164a.a, P.pastoris) is 164 a.a., with molecular weight of 18-22 kDa.

HY-P78378

	VEGF165 Protein, Human (HEK293, His-Avi) VEGF-AA; VEGF; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609	Human	HEK293
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF165 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF165 Protein, Human (HEK293, His-Avi) is 165 a.a., with molecular weight of 28-32 kDa.

HY-P78228

	VEGF121 Protein, Human (Biotinylated, HEK293, His-Avi) VEGF-AA; VEGF; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609	Human	HEK293
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF121 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF121 Protein, Human (Biotinylated, HEK293, His-Avi) is 121 a.a., with molecular weight of ~18 kDa & 22-25 kDa, respectively.

HY-P78229

	VEGF165 Protein, Human (Biotinylated, HEK293, His-Avi) 1 Publications Verification VEGF-AA; VEGF; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609	Human	HEK293
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF165 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF165 Protein, Human (Biotinylated, HEK293, His-Avi) is 165 a.a., with molecular weight of 28-32 kDa.

HY-P74616

	*Prokineticin-1/EG-VEGF* Protein, Human (sf9, His)** Prokineticin-1; EG-VEGF; Mambakine; PROK1	Human	Sf9 insect cells
	Prokineticin-1/EG-VEGF protein is a potent regulator of gastrointestinal smooth muscle contraction and affects intestinal motility. Its multifaceted effects extend to capillary endothelial cells, inducing proliferation, migration, and fenestration and are specific to certain cell types. Prokineticin-1/EG-VEGF Protein, Human (sf9, His) is the recombinant human-derived Prokineticin-1/EG-VEGF protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Prokineticin-1/EG-VEGF Protein, Human (sf9, His) is 105 a.a., with molecular weight of ~15 kDa.

HY-P77864

	VEGF-C Protein, Human (HEK293, His-Avi) VEGFC; VEGF-CC; VEGFc; Flt4-L; VRP	Human	HEK293
	VEGF-C Protein, a crucial member of the PDGF/VEGF growth factor family, plays a role in vital cellular signaling pathways. As part of this family, VEGF-C likely shares characteristics with related proteins, promoting cell growth, angiogenesis, and lymphangiogenesis. Membership in the PDGF/VEGF growth factor family underscores its role in vascular and lymphatic development regulation. Studying VEGF-C enhances understanding of its functions, potential therapeutic applications, and impact on tissue development. Further exploration can deepen comprehension of VEGF-C's contribution to physiological and pathological conditions. VEGF-C Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF-C protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of VEGF-C Protein, Human (HEK293, His-Avi) is 125 a.a., with homodimer molecular weight of ~23-30 kDa.

HY-P78016

	*Prokineticin-1/EG-VEGF* Protein, Mouse (HEK293, Fc)** Prokineticin-1; EG-VEGF; Mambakine; PROK1	Mouse	HEK293
	Prokineticin-1/EG-VEGF protein induces strong contraction of gastrointestinal smooth muscle and stimulates capillary endothelial cell proliferation, migration, and fenestration. It promotes enteric neural crest cell proliferation and differentiation but not migration. Prokineticin-1/EG-VEGF Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Prokineticin-1/EG-VEGF protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Prokineticin-1/EG-VEGF Protein, Mouse (HEK293, Fc) is 86 a.a., with molecular weight of 38-48 kDa.

HY-P72280

	VEGF-A Protein, Pig (His) VEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	Pig	E. coli
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Pig (His) is the recombinant pig-derived VEGF-A protein, expressed by E. coli , with N-6*His labeled tag. The total length of VEGF-A Protein, Pig (His) is 164 a.a., with homodimer molecular weight of ~23.2 kDa.

HY-P77865

	VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) VEGFC; VEGF-CC; VEGFc; Flt4-L; VRP	Human	HEK293
	VEGF-C protein is an important member of the PDGF/VEGF growth factor family and plays a role in important cell signaling pathways. As part of this family, VEGF-C may share features with related proteins that promote cell growth, angiogenesis, and lymphangiogenesis. VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) is 125 a.a., with homodimer molecular weight of ~23-30 kDa.

HY-P72280AF

	*Animal-Free VEGF* Protein, Pig (His)** VEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	Pig	E. coli
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. Animal-Free VEGF Protein, Pig (His) is the recombinant pig-derived animal-FreeVEGF protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free VEGF Protein, Pig (His) is 164 a.a., with molecular weight of ~20.16 kDa.

HY-P70458A

	VEGF165 Protein, Human (HEK293, C-His) 1 Publications Verification Vascular Endothelial Growth Factor Isoform 165; VEGF165	Human	HEK293
	VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF165 Protein, Human (HEK293, C-His) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of VEGF165 Protein, Human (HEK293, C-His) is 165 a.a., with molecular weight of 20-23 kDa.

HY-P700496

	VEGF-A Protein, Rabbit (His-SUMO) VEGFA; VPF; VEGF; MVCD1; vascular endothelial growth factor A; vascular permeability factor	Rabbit	E. coli
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (His-SUMO) is the recombinant Rabbit-derived VEGF-A protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag. The total length of VEGF-A Protein, Rabbit (His-SUMO) is 461 a.a., with molecular weight of 65.7 kDa.

HY-P700497

	VEGF-A Protein, Rabbit (P. pastoris, His) VEGFA; VPF; VEGF; MVCD1; vascular endothelial growth factor A; vascular permeability factor	Rabbit	P. pastoris
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (P. pastoris, His) is the recombinant Rabbit-derived VEGF-A protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of VEGF-A Protein, Rabbit (P. pastoris, His) is 461 a.a., with molecular weight of 51.7 kDa.

HY-P7110

	VEGF165 Protein, Human (P.pastoris) VEGF-AA; rHuVEGF165; VPF; Folliculostellate cell-derived growth factor; Glioma-derived endothelial cell mitogen	Human	P. pastoris
	VEGF165 Protein, Human (P.pastoris) is a Vascular Endothelial Growth Factor A (VEGF-A) isoform. VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis.

HY-P7110A

	VEGF165 Protein, Human (HEK293) 3 Publications Verification VEGF-AA; rHuVEGF165; VPF; Folliculostellate cell-derived growth factor; Glioma-derived endothelial cell mitogen	Human	HEK293
	VEGF165 Protein, Human (HEK293) is a Vascular Endothelial Growth Factor A (VEGF-A) isoform. VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis.

HY-P70495

	VEGF-DD Protein, Human (HEK293, His) Vascular Endothelial Growth Factor D; VEGF-D; c-Fos-Induced Growth Factor; FIGF; VEGFD	Human	HEK293
	VEGF-DD protein is a potent growth factor in angiogenesis, lymphangiogenesis, and endothelial cell growth, playing a key role in stimulating cell proliferation, migration, and affecting vascular permeability. It may be involved in the formation of veins and lymphatic vasculature during embryogenesis, suggesting that it plays a key role in vascular development. VEGF-DD Protein, Human (HEK293, His) is the recombinant human-derived VEGF-DD protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-DD Protein, Human (HEK293, His) is 109 a.a., with molecular weight of ~18.0 kDa.

HY-P70501

	VEGF-CC Protein, Human (196a.a, HEK293, His) Vascular Endothelial Growth Factor C; VEGF-C; Flt4 Ligand; Flt4-L; Vascular Endothelial Growth Factor-Related Protein; VRP; VEGFC	Human	HEK293
	The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-CC Protein, Human (196a.a, HEK293, His) is the recombinant human-derived VEGF-CC protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-CC Protein, Human (196a.a, HEK293, His) is 196 a.a., with molecular weight of 25-30 kDa.

HY-P7314

	VEGF-D Protein, Human (HEK293) rHuVEGF-D; Vascular endothelial growth factor D; FIGF	Human	CHO
	VEGF-D Protein, Human (HEK293) is a regulator of both angiogenesis and lymphangiogenesis.

HY-P71515

	BamA Protein, E.coli (Myc, His) bamA; yaeT; yzzN; yzzY; b0177; JW0172Outer membrane protein assembly factor BamA; OMP85	E.coli	E. coli
	BamA is a key member of the outer membrane protein assembly complex (Bam), which concentrates the assembly of β-barrel proteins into the outer membrane. Together with BamD, BamA forms the core mechanism of this process, which relies on the coordinated action of all five subunits. BamA Protein, E.coli (Myc, His) is the recombinant E. coli-derived BamA protein, expressed by E. coli , with N-10*His, C-Myc labeled tag. The total length of BamA Protein, E.coli (Myc, His) is 250 a.a., with molecular weight of ~36.0 kDa.

HY-P73313

	Neuropilin-2 Protein, Human (HEK293, Fc) Neuropilin-2; NRP2; VEGF165R2	Human	HEK293
	Neuropilin-2 Protein, a pivotal player, serves as a high-affinity receptor for semaphorins 3C and 3F, VEGF-165, VEGF-145, and PLGF-2. Beyond its role in growth factors, Neuropilin-2 plays a critical function in microbial infection, acting as a receptor facilitating pentamer-dependent entry of human cytomegalovirus into epithelial and endothelial cells. Neuropilin-2 Protein, Human (HEK293, Fc) is the recombinant human-derived Neuropilin-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Neuropilin-2 Protein, Human (HEK293, Fc) is 833 a.a., with molecular weight of 119-129 kDa.

HY-P73353

	PDGF-CC Protein, Human (HEK293, Fc) PDGF-C; Platelet derived growth factor C; VEGF-E; SCDGF	Human	HEK293
	PDGF-CC is a multifunctional growth factor that plays a crucial role in embryonic development, cellular processes, and tissue formation. It is essential for embryonic skeletal development, skin morphogenesis, and wound healing. PDGF-CC Protein, Human (HEK293, Fc) is the recombinant human-derived PDGF-CC protein, expressed by HEK293 , with N-hFc labeled tag. The total length of PDGF-CC Protein, Human (HEK293, Fc) is 111 a.a., with molecular weight of ~45 kDa.

HY-P73354

	PDGF-CC Protein, Mouse (HEK293, Fc) PDGF-C; Platelet derived growth factor C; VEGF-E; SCDGF	Mouse	HEK293
	The PDGF-CC protein is a key growth factor that plays crucial roles in a variety of cellular processes, including embryonic development, cell proliferation, migration, survival, and chemotaxis. It has potent mitogenic and chemoattractant properties and is essential during embryonic skeletal formation, craniofacial development, palate development, skin morphogenesis and wound healing stages. PDGF-CC Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived PDGF-CC protein, expressed by HEK293 , with N-hFc labeled tag. The total length of PDGF-CC Protein, Mouse (HEK293, Fc) is 111 a.a., with molecular weight of ~46 kDa.

HY-P73719

	PDGF-CC Protein, Mouse (P.pastoris, His) PDGF-C; Platelet derived growth factor C; VEGF-E; SCDGF	Mouse	P. pastoris
	The PDGF-CC protein is a key growth factor that plays crucial roles in a variety of cellular processes, including embryonic development, cell proliferation, migration, survival, and chemotaxis. It has potent mitogenic and chemoattractant properties and is essential during embryonic skeletal formation, craniofacial development, palate development, skin morphogenesis and wound healing stages. PDGF-CC Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived PDGF-CC protein, expressed by P. pastoris , with N-His labeled tag. The total length of PDGF-CC Protein, Mouse (P.pastoris, His) is 111 a.a., with molecular weight of ~14.4 kDa.

Cat. No.	Product Name	Chemical Structure

HY-B0239S2

Threo-Chloramphenicol-d6

Threo-Chloramphenicol-d₆ is the deuterium labeled Chloramphenicol[1]. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research[2][3][4].

HY-121356S1

Carebastine-d5 Methyl Ester
Carebastine-d₅ Methyl Ester is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner[1]. Carebastine suppresses the expression of macrophage migration inhibitory factor[2].

HY-121356S

Carebastine-d5
Carebastine-d₅ is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner[1]. Carebastine suppresses the expression of macrophage migration inhibitory factor[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks